Previous Article | Next Article ![]()
Infection and Immunity, April 2005, p. 2157-2163, Vol. 73, No. 4
0019-9567/05/$08.00+0 doi:10.1128/IAI.73.4.2157-2163.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Department of Oral Microbiology, Asahi University School of Dentistry, Gifu,1 Division of Infectious Genetics, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo,3 Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan,4 Division of Microbiology and Molecular Genetics, School of Medicine, Loma Linda University, Loma Linda, California2
Received 8 October 2004/ Returned for modification 11 November 2004/ Accepted 8 December 2004
|
|
|---|
PG1828-LPS) showed nearly the same ladder-like patterns in silver-stained gels as a preparation of LPS from a wild-type strain (WT-LPS), as well as Limulus amoebocyte lysate activities that were similar to those of the WT-LPS preparation. However, the ability of the
PG1828-LPS preparation to activate NF-
B in TLR2-expressing cells was markedly attenuated. Cytokine production by human gingival fibroblasts was also decreased in response to the
PG1828-LPS preparation in comparison with the WT-LPS preparation, and the activity was comparable to the stimulation of highly purified lipid A of P. gingivalis by TLR4. Further, lethal toxicity was rarely observed following intraperitoneal injection of the PG1828-deficient mutant into mice compared to that with the wild-type strain, while the
PG1828-LPS preparation showed no lethal toxicity. Taken together, these results clearly indicate that PG1828LP plays an essential role in inflammatory responses and may be a major virulence factor of P. gingivalis. |
|
|---|
Among these virulence factors, LPS is well known as a major component of the outer membranes of gram-negative bacteria, and it exhibits powerful immunostimulatory and inflammatory activities (32). However, P. gingivalis LPS has a lower level of endotoxic potency than other types of enterobacterial LPSs (21, 27), while it and its active center, lipid A, have been shown to have other properties, such as an ability to activate cells from LPS-hyporesponsive C3H/HeJ mice as well as those from LPS-responsive C3H/HeN mice (18, 42).
Toll-like receptor 4 (TLR4) and its accessory protein MD-2 are known to function as signaling receptors for various LPSs (44), and C3H/HeJ mice have been demonstrated to be hyporesponders, due to a natural point mutation of TLR4 (30). Further, TLR2 has been shown to be an essential signal-transducing molecule for P. gingivalis LPS preparations (4, 13), although P. gingivalis LPS is thought to be associated with quite different lipid A phosphorylation and acylation patterns (25). More recently, Darveau et al. (6) indicated that P. gingivalis LPS activates cells through both TLR2 and TLR4, because it possesses multiple lipid A species. In contrast, it was also reported that P. gingivalis LPS exerted antagonistic effects toward TLR4-dependent cell activation by Escherichia coli LPS (5, 45).
We previously demonstrated that highly purified lipid A from P. gingivalis and its synthetic counterpart activated cells via a TLR4/MD-2-dependent pathway but not via TLR2, which was in contrast to the cell activation activities of a P. gingivalis LPS preparation, which were shown to occur via TLR2 (28). In addition, we recently showed that a PG1828-encoded lipoprotein (PG1828LP) was able to be separated from a P. gingivalis LPS preparation by using a detergent-modified phenol-water extraction method, and we found that it exhibited TLR2-dependent cell activation and possessed strong cell-activating capacities in comparison with E. coli LPS (11). In the present study, we generated a PG1828-deficient mutant of P. gingivalis and showed that its LPS preparation significantly reduced cell activation via TLR2.
|
|
|---|
was used for cloning and was grown on Luria-Bertani agar base (Difco) or in LB broth (Difco). Plasmid pVA2198, which carries the ermF-ermAM gene and confers erythromycin resistance, was also used (9). For selection or maintenance of the plasmid-containing strains, antibiotics (1 µg of clindamycin per ml for P. gingivalis and 100 µg of ampicillin per ml for E. coli) were added to the media. DNA sequencing. A DNA fragment from PG1825 to PG1829 of P. gingivalis 381 was obtained by PCR, using synthesized primers designed according to the DNA sequence of P. gingivalis W83 (24). The sequence of the product was determined with the ABI PRISM 3100-Avant automated DNA sequencer (Applied Biosystems, Foster City, Calif.), using the BigDye Terminator version 3.1 cycle sequencing kit.
Construction of the PG1828-deficient mutant.
To generate a mutant deficient in the PG1828-encoded lipoprotein, plasmid DNA constructs were made by replacing the PG1828 gene with an ermF-ermAM cassette (Fig. 1A). The BamHI/EcoRI fragment of pVA2198 containing the ermF-ermAM gene was ligated with BamHI/EcoRI-digested pBluescript II SK(+) (Stratagene, La Jolla, Calif.). The upstream flanking regions, including the entire PG1825, PG1826, and PG1827 genes, and the downstream flanking regions, including the entire PG1829 gene, were amplified from P. gingivalis 381 chromosomal DNA by using the following primers: 1825-dw (5'-CGCCGGTCTAGACTAAGGATTGATTAAAC-3' [the XbaI site is underlined]), 1827-dw (5'-TTTATTACTAGTGTGTGTGCTGAGCAGGC-3' [the SpeI site is underlined]), 1829-dw (5'-GAGTGTGATATCCGCATGGCTATTCCTTT-3' [the EcoRV site is underlined]), and 1829-up (5'-AAGTATCTCGAGCTGCTCGCCTTTTGATT-3' [the XhoI site is underlined]). Fragments digested with enzymes were cloned into pBluescript II SK(+) carrying the ermF-ermAM gene and transformed into E. coli DH5
by standard techniques (34). The BssHII fragment of the resulting construct containing the ermF-ermAM gene (Fig. 1A) was transformed into P. gingivalis 381 by electroporation as previously described, with some modifications (22, 33). Briefly, P. gingivalis cells were anaerobically grown at 37°C in 50 ml of BHI broth containing 0.5% yeast extract (Difco), 5 µg of hemin per ml, and 1 µg of vitamin K3 per ml and then were washed with cold distilled water twice and resuspended in 200 µl of 1 mM MgCl2 containing 10% glycerol. Linearized DNA samples (10 µg) were added to an 80-µl cell suspension and electroporated in a 0.1-cm-diameter cuvette at 200
, 1.8 kV, and 25 µF (Gene Pulser II system; Bio-Rad, Hercules, Calif.). The cells were then immediately mixed with 10 ml of prewarmed BHI broth containing 0.5% yeast extract, 5 µg of hemin per ml, and 1 µg of vitamin K3 per ml and incubated anaerobically at 37°C for 16 h, after which they were plated onto BHI agar plates containing 0.5% yeast extract, 5 µg of hemin per ml, 1 µg of vitamin K3 per ml, and 1 µg of clindamycin per ml. The plates were incubated for 5 to 7 days anaerobically at 37°C to develop colonies.
![]() View larger version (23K): [in a new window] |
FIG. 1. Inactivation of PG1828 in P. gingivalis. (A) Construction of a PG1828-deficient mutant of P. gingivalis strain 381 by allelic exchange mutagenesis with an ermF-ermAM antibiotic resistance cassette (as described in Materials and Methods). (B) Predicted maps of the genomes of the wild-type and the PG1828-deficient mutant. Arrowheads indicate the numbers and positions of oligonucleotide primers for PCR analysis (as described in Materials and Methods). (C) PCR analysis of WT and PG1828. Numbers above the lanes indicate the primer pairs (B) used for the PCR analysis. Lane M, DNA marker; left margin, molecular sizes.
|
DNA probes and Southern blot analysis. An ermF-ermAM probe was prepared as a 2.1-kb fragment and amplified from pVA2198 by using the primers erm-up (5'-CCGCTATTGCTTTTTTGCTC-3') and erm-dw (identical to primer 3). The DNA probe was labeled with alkaline phosphatase (ALP) by using the AlkPhos direct labeling module (Amersham Biosciences, Piscataway, N.J). BamHI-digested chromosomal DNA samples from the wild-type strain and the PG1828-deficient mutant were electrophoresed on a 1% agarose gel and then transferred to a HyBond-N+ nylon membrane (Amersham Biosciences) by using an alkaline blotting protocol. The membrane was prehybridized at 60°C for 15 min in a hybridization buffer and then hybridized with an ALP-labeled probe at 60°C for 2 h. At the end of the procedure, the membrane was washed under highly stringent conditions, and then a chemiluminescence detection assay was carried out with the CDP-Star detection reagent (Amersham Biosciences). The membrane was exposed to X-ray film for 30 min, and signals were developed for each strain.
RT-PCR analysis. Total RNA samples were isolated from the wild-type strain and PG1828-deficient mutant by using TRIzol reagent (Gibco BRL, Gaithersburg, Md.) according to the manufacturer's instructions and then were treated with RNase-free DNase (TaKaRa, Shiga, Japan) based on a method described previously (7). Reverse transcription (RT) was conducted with avian myeloblastosis virus reverse transcriptase (TaKaRa) with random hexamers, and the cDNA was subjected to PCR to amplify the PG1828 gene by using the primers 1828-up (identical to primer 4) and 1828-dw (5'-TTGAGCGGCTTGTTCAG-3'). For a negative control, a non-RT sample was also amplified by PCR.
LPS preparation and bacterial component. Extraction of LPS by a phenol-water method was performed as described previously (11). The preparation was repurified by a detergent-modified phenol-water extraction method, as described by Manthey and Vogel (20), and visualized by Tris-glycine sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with a 15% polyacrylamide gel and periodic acid-silver (Ag) staining (43). P. gingivalis lipid A was isolated by aqueous acetic acid hydrolysis of an LPS preparation from the wild-type strain, followed by successive separation by thin-layer chromatography, as previously described (28). E. coli O55:B5 LPS was obtained from Sigma Chemical Co. (St. Louis, Mo.).
LAL assay.
Various doses of the repurified LPS preparations from the wild-type strain (WT-LPS) and PG1828-deficient mutant (
PG1828-LPS) were mixed separately with Limulus amoebocyte lysate (LAL) reagent and then incubated at 37°C for 30 min, after which the activities were determined with a quantitative chromogenic assay (Seikagaku Kogyo, Tokyo, Japan).
Visualization of PG1828LP. The LPS preparation was subfractionated by hydrophobic interaction chromatography according to our previously reported method (11), with a slight modification. Briefly, the LPS preparation was subjected to chromatography on an octyl-Sepharose 4FF column (Amersham Biosciences) and eluted with 0.1 M of ammonium acetate with a linear gradient of 1-propanol (15 to 60%). PG1828LP in the LPS preparation was separated by Tris-glycine SDS-PAGE with a 15% polyacrylamide gel and visualized by Coomassie brilliant blue (CBB) staining with Simply Blue SafeStain (Invitrogen Corp., Carlsbad, Calif.).
Luciferase assay.
Interleukin-3 (IL-3)-dependent murine Ba/F3 pro-B cells stably expressing p55Ig
Luc and an NF-
B/DNA binding activity-dependent luciferase reporter construct (Ba/
B), murine TLR2 and a p55Ig
Luc reporter construct (Ba/mTLR2), and murine TLR4/MD-2 and a p55Ig
Luc reporter construct (Ba/mTLR4/mMD-2), were used to detect NF-
B-dependent luciferase activity, as described previously (12, 28). Briefly, the cells were inoculated onto 96-well plates at 105 cells/100 µl of RPMI 1640 supplemented with 10% fetal bovine serum and were stimulated separately with the indicated doses of the WT-LPS or
PG1828-LPS preparations. After 4 h at 37°C, 100 µl of Bright-Glo luciferase assay reagent (Promega, Madison, Wis.) was added to each well, and luminescence was quantified with a luminometer (Turner Designs luminometer model TD-20/20; Promega). E. coli LPS was used as a positive control for TLR4/MD-2 ligand.
Human embryonic kidney 293 cells were transiently cotransfected with 1 µg of a human TLR2 expression vector or its empty vector, 50 ng of pNF-
B Luc reporter plasmid (Stratagene), and 50 ng of pRL-TK (Promega) by using Lipofectamine 2000 (Invitrogen Corp.). Twenty-four hours after transfection, the cells were stimulated with the indicated doses of the WT-LPS or
PG1828-LPS preparations for 12 h, after which luciferase activity was measured by using a dual-luciferase reporter assay system (Promega).
Mice. BALB/c mice (male, 8 weeks old) were obtained from Japan SLC, Inc., Shizuoka, Japan. The animals received humane care in accordance with our institutional guidelines and the legal requirements of Japan.
Cytokine assay.
Human gingival fibroblasts were prepared from clinically normal gingival tissues according to a method similar to that described previously (11). After written informed consent under a protocol approved by the Institutional Review Board of Asahi University was received, tissue samples were collected. The cells were cultured in
-MEM (Sigma Chemical Co.) containing 10% fetal bovine serum, 50 µg of gentamicin per ml, and 50 ng of amphotericin B per ml at 37°C in a 5% (vol/vol) CO2 atmosphere and then were used for the assays at the 5th and 13th passages. The cells were stimulated with the indicated doses of the test specimens for 24 h at 37°C. Following incubation, the culture supernatants were collected and analyzed for secreted IL-8 by using an enzyme-linked immunosorbent assay (ELISA) kit (GT, Minneapolis, Minn.). In some experiments, mice were intraperitoneally injected with 100 µg of WT-LPS or
PG1828-LPS preparation along with 18 mg of D-galactosamine (D-GalN). Serum specimens from the two groups (each containing five mice) were obtained 1 h after the injection of LPS preparations. These specimens were analyzed for tumor necrosis factor alpha (TNF-
) and IL-6 concentrations by using an ELISA kit (eBioscience, San Diego, Calif.).
Virulence model. It was previously demonstrated that P. gingivalis LPS exhibited weak lethal toxicity (40). To sensitize mice to the lethal effects of LPS preparations, we used D-GalN (10). Briefly, a model for lethal toxicity in mice was established with an intraperitoneal injection of the indicated doses of the LPS preparations along with 18 mg of D-GalN diluted in 500 µl of saline. For some of the experiments, mice were injected peritoneally with the indicated doses of living P. gingivalis cells. Survival was monitored for up to 7 days, and the 50% lethal dose (LD50) was calculated as previously described (16).
Analysis of enzymatic activity. The amounts of cell-associated enzymes in the wild-type strain and the PG1828-deficient mutant were determined by a method similar to that described previously (3). Briefly, the cells were centrifuged and suspended in phosphate-buffered saline for enzyme analysis. An API ZYM chromogenic assay system (Bio Mérieux, Marcy-l'Etoile, France) was used for estimation of enzyme levels, and the intensity of the color reaction was graded semiquantitatively in comparison to a standard API ZYM color reaction chart. The results were determined from three independent experiments.
Statistical analysis.
IL-8 production induced by the various doses of
PG1828-LPS was assessed with a one-way analysis of variance, using the Bonferroni or Dunn method, and the results are presented as the mean ± standard error of the mean. Serum cytokine concentrations in different experimental groups were analyzed for statistical significance by using Welch's t test.
Nucleotide sequence accession number. The DNA sequence obtained in this study has been entered into the DDBJ database under accession number AB189170.
|
|
|---|
![]() View larger version (41K): [in a new window] |
FIG. 2. (A) Detection of ermF-ermAM by Southern blot analyses of BamHI-digested chromosomal DNA samples from the wild-type and PG1828-deficient mutant strains. BamHI-digested chromosomal DNA was electrophoresed on a 1% agarose gel (lane M, DNA marker; lane 1, WT; lane 2, PG1828) and transferred to a nylon membrane. The membrane was hybridized with an ALP-labeled ermF-ermAM probe, and a chemiluminescence detection assay was carried out (lane 3, WT; lane 4, PG1828). Left margin, molecular sizes. (B) RT-PCR analysis of PG1828 mRNA expression in P. gingivalis. The presence (+) or absence () of RT in each RT-PCR mixture is indicated above the lanes.
|
PG1828-LPS preparation showed nearly the same ladder-like pattern as the WT-LPS preparation on Ag-stained gels (Fig. 3A). Further, the clotting activities of the
PG1828-LPS preparation in an LAL assay were the same as those of the WT-LPS preparation (Fig. 3B). These results indicated that the
PG1828-LPS preparation was equivalent to the LPS molecule of the WT-LPS preparation. We previously showed that PG1828LP could be visualized as a 16-kDa band by SDS-PAGE with CBB staining (11); therefore, the absence of PG1828LP in the
PG1828-LPS preparation was confirmed by protein visualization. These preparations were subfractionated by using hydrophobic interaction chromatography to enrich PG1828LP as described previously (11). PG1828LP was then concentrated into specific fractions, and a major CBB-positive band was found at 16 kDa in the WT-LPS preparation; however, no CBB-positive 16-kDa band was found in the
PG1828-LPS preparation (Fig. 3C).
![]() View larger version (39K): [in a new window] |
FIG. 3. Characterization of the PG1828-LPS preparation. (A) Tris-glycine SDS-PAGE was performed with a 15% polyacrylamide gel, and proteins were visualized by Ag staining. Lanes: 1, WT-LPS; 2, PG1828-LPS. (B) The indicated doses of the LPS preparations were mixed with LAL reagent, and LAL activity was determined with a quantitative chromogenic assay. Representative results from three independent experiments are shown. (C) The LPS preparation was subjected to chromatography on an octyl-Sepharose 4FF column and eluted with 0.1 M ammonium acetate with a linear gradient of 1-propanol (15 to 60%). The components in the specific fraction were separated by Tris-glycine SDS-PAGE with a 15% polyacrylamide gel, and PG1828LP was visualized by CBB staining. Lanes: MP, protein marker; 1, WT-LPS preparation; 2, PG1828-LPS preparation. Left margin, molecular sizes.
|
B activation than the
PG1828-LPS preparation from the PG1828LP-deficient mutant, whereas only marginal murine TLR4/MD-2-dependent NF-
B activation compared to that with E. coli LPS was observed in both LPS preparations. The same results were obtained for the human TLR2-expressing cell line HEK293/hTLR2.
![]() View larger version (22K): [in a new window] |
FIG. 4. TLR-dependent activation of the PG1828-LPS preparation. (A) Ba/ B, Ba/mTLR2, and Ba/mTLR4/mMD-2 cells were stimulated with the indicated doses of WT-LPS or PG1828-LPS preparations for 4 h. E. coli LPS was used as a positive control for TLR4/MD-2 ligand. (B) HEK293/hTLR2 and HEK293/Empty were stimulated with the indicated doses of the WT-LPS or PG1828-LPS preparations for 12 h. NF- B activation was measured with a luciferase assay. Results are shown as relative luciferase activity, which was determined as the ratio of stimulated to nonstimulated activity.
|
PG1828-LPS preparation by using human gingival fibroblasts, which constitutively express TLR2 and TLR4 (39).
PG1828-LPS showed a lower level of IL-8 production than the WT-LPS preparation, which was nearly the same as that of highly purified P. gingivalis lipid A (Fig. 5). These results demonstrated that PG1828LP is a major cell-activating component in the P. gingivalis LPS preparation.
![]() View larger version (13K): [in a new window] |
FIG. 5. Cytokine production by human gingival fibroblasts stimulated with the PG1828-LPS preparation. The cells were stimulated with the indicated doses of the WT-LPS preparation, the PG1828-LPS preparation, or P. gingivalis lipid A for 24 h. IL-8 production was analyzed by ELISA. Data are shown as the means ± standard error of the means from three independent experiments. P. gingivalis lipid A was used for TLR4/MD-2 ligand in the P. gingivalis LPS preparation, and the data were described previously (11). *, significantly different from the mean value of each specimen dose against the PG1828-LPS preparation (P < 0.01).
|
PG1828-LPS preparation induced no lethal activities at up to 100 µg/mouse. Further, the mice injected with the
PG1828-LPS preparation showed a significant decrease in TNF-
and IL-6 concentrations in serum compared to those injected with the WT-LPS preparation (Fig. 6). |
View this table: [in a new window] |
TABLE 1. Lethal toxicity of P. gingivalis cells in BALB/c mice
|
|
View this table: [in a new window] |
TABLE 2. Lethal toxicity of P. gingivalis LPS preparations in D-GalN-sensitized BALB/c mice
|
![]() View larger version (13K): [in a new window] |
FIG. 6. Cytokine concentrations in sera of mice treated with the PG1828-LPS preparation. Mice were intraperitoneally injected with 100 µg of WT-LPS or PG1828-LPS preparations along with 18 mg of D-GalN, and then serum specimens were collected 1 h after injection of the LPS preparations. TNF- and IL-6 concentrations were analyzed by ELISA. Error bars indicate standard errors of the means. *, significantly different from the mean value for the WT-LPS preparation (P < 0.01).
|
|
|
|---|
In the present study, we used a genetic approach to further examine the participation of lipoprotein in a P. gingivalis LPS preparation. The PG1828-deficient mutant failed to express PG1828 mRNA (Fig. 2), resulting in the disappearance of the 16-kDa CBB-positive stained band in the
PG1828-LPS preparation assay results (Fig. 3). These findings indicate that the desired lipoprotein, PG1828LP, was successfully deleted from the deficient mutant. Further, the
PG1828-LPS and WT-LPS preparations each showed a ladder-like pattern in Ag-stained gels, indicating the presence of a glycoconjugate with repeating units, which is a characteristic of LPS molecules, and there were no differences in LAL clotting activity between the two preparations (Fig. 3). On the other hand, the
PG1828-LPS preparation exhibited a marked reduction of activation of TLR2-expressing cells compared to the WT-LPS preparation, while it slightly activated human gingival fibroblasts in a manner comparable to the stimulation of highly purified P. gingivalis lipid A by TLR4/MD-2 (Fig. 4 and 5). These results indicate that the cell activation induced by the
PG1828-LPS preparation may have been be due to P. gingivalis LPS molecules.
Several bacterial lipoproteins have been identified and are thought to play important roles in bacterial pathogenesis. It was previously shown that a 47-kDa lipoprotein (GNA47) of Neisseria meningitidis was associated with peptidoglycan metabolism, cell separation, and cell membrane architecture and that it also caused bacteremia and mortality in infant rats (1). In addition, the spirochetal lipoprotein of OspC-deficient Borrelia burgdorferi was demonstrated to be unable to invade tick salivary glands, which is a critical step in transmission from the arthropod vector to mammalian host (29). Recently, a murein lipoprotein-deficient mutant of Salmonella enterica serovar Typhimurium was demonstrated to be nonvirulent in a murine lethal model (36). In the present study, the PG1828-deficient mutant produced a significantly reduced mortality rate in mice in comparison to the wild-type strain (Table 1), and an intraperitoneal injection of the
PG1828-LPS preparation was not toxic in D-GalN-sensitized mice, even at the highest dose tested (100 µg/mouse) (Table 2). In another study, the lipoprotein obtained from E. coli cells was found to induce lethal shock against D-GalN-sensitized mice, and a heat-killed preparation from a lipoprotein-deficient E. coli mutant was less efficient than that from wild-type E. coli (46).
It was reported that various proteases were secreted by P. gingivalis organisms (17, 26, 31). We found here that both the wild-type and the PG1828-deficient mutant exhibited trypsin-like protease activity (data not shown). The intrinsic protease may digest PG1828LP released from the organisms. The protease, however, seems not to inhibit the virulence of PG1828LP (Table 1). Since mature PG1828LP contains two lysine at the 6th and 42nd amino acid residues from N-terminally lipidated cysteine, tryptic digestion of the lipoprotein gives three peptide fragments, i.e., residues 1 to 6, 7 to 42, and 43 to 52. Our previous study showed that the TLR2-mediated immunostimulating activity of isolated PG1828LP was reduced only about 10-fold by trypsin digestion and that the lipopeptide fragment from residue 1 to 6 still retained the activity (11). It has also been reported that proteinase K or trypsin digestion fails to inhibit the activities of lipoproteins from other bacterial species (8, 35). Further, synthetic lipopeptides with short peptides, such as Pam3CSK4, show strong TLR2-mediated activities (2). Thus, released PG1828LP, which exhibits immunostimulating activity in vivo and is possibly accessible to intrinsic proteases, acts as a virulence factor of P. gingivalis, even if it is digested.
In conclusion, we showed that PG1828LP, a PG1828-encoded lipoprotein from P. gingivalis, is a principal component for cell activation and virulence of the organism. The reduced activity of the PG1828-deficient mutant and its LPS preparation in proinflammatory cytokine production and lethal toxicity suggests that PG1828LP is a virulence factor associated with periodontal diseases.
We thank Chieko Kanamori for technical assistance and Mark Benton for critical reading of the manuscript.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»